Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
EGFR is a potential target for new anticancer therapy in head and neck squamous cell
carcinoma, because blocking the EGFR by a monoclonal antibody results in inhibition of the
stimulation of the receptor, therefore, in inhibition of cell proliferation, enhanced
apoptosis, and reduced angiogenesis, invasiveness and metastases. The study hypothesis is
that neo-adjuvant Erbitux-based chemotherapy followed by surgery and radiotherapy for locally
advanced oral/oropharyngeal cancer could benefit the patients on prognosis. The endpoints of
this study are the pathological complete response after neo-adjuvant Erbitux-based
chemotherapy followed by surgery and radiotherapy, the survival rate, and the safety.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborators:
Fudan University Second Military Medical University Tongji University